---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053878"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2026-08-06T12:02:17+00:00"
generated_at: "2026-08-06T12:05:45.862517+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q2 net loss $42.1M; IND/CTA clearances for PM577a, arbitration win for PM647

## Summary
- Net loss of $42.1M for Q2 2026 vs $52.6M in Q2 2025; R&D expenses $33.4M.
- Cash, equivalents, investments, restricted cash $108.8M as of June 30, 2026; runway into 2027.
- FDA cleared IND for PM577a in Wilson disease; Medsafe cleared CTA in New Zealand; global Phase 1/2 study startup underway.
- Arbitration with Beam Therapeutics resolved favorably; PM647 rights secured; IND/CTA submission expected Q3 2026.
- FDA granted RMAT designation to PM359 for CGD; BLA submission planned for 1H 2027.

## SEC filing metadata
- accession: 0001628280-26-053878
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2026-08-06T12:02:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/0001628280-26-053878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/prme-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053878
- JSON: https://secwatch.observer/filing/0001628280-26-053878.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.